Breaking News Instant updates and real-time market news.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

, LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

06:59
11/23/16
11/23
06:59
11/23/16
06:59

Citi pegs potential Biogen downside to $287 on Lilly failure

In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

  • 29

    Nov

  • 04

    Dec

BIIB Biogen
$318.11

-0.21 (-0.07%)

11/07/16
MZHO
11/07/16
INITIATION
Target $290
MZHO
Neutral
Biogen initiated with a Neutral at Mizuho
Mizuho analyst Salim Syed initiated Biogen with a Neutral rating and a $290 price target.
11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.

TODAY'S FREE FLY STORIES

GLOW

Glowpoint

$0.33

-0.0056 (-1.68%)

15:08
01/22/18
01/22
15:08
01/22/18
15:08
Hot Stocks
Breaking Hot Stocks news story on Glowpoint »

Glowpoint trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTT

inTEST

$8.84

-0.26 (-2.86%)

15:04
01/22/18
01/22
15:04
01/22/18
15:04
Initiation
inTEST initiated  »

inTEST initiated with $11…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEPT

Neptune Technologies

$3.05

0.14 (4.81%)

15:00
01/22/18
01/22
15:00
01/22/18
15:00
Options
New positions opened in Neptune Tech February puts and calls »

New positions opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:55
01/22/18
01/22
14:55
01/22/18
14:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

PTEN

Patterson-UTI

$24.48

0.6 (2.51%)

14:54
01/22/18
01/22
14:54
01/22/18
14:54
Periodicals
Patterson-UTI confirms responding to fire at Oklahoma rig, FOX23 says »

Patterson-UTI confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

MRNS

Marinus Pharmaceuticals

$6.83

-0.05 (-0.73%)

14:50
01/22/18
01/22
14:50
01/22/18
14:50
Options
Notable call buying in Marinus Pharmaceuticals as shares see relative strength »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

, XLI

Industrial Select Sector SPDR

$79.45

-0.24 (-0.30%)

14:49
01/22/18
01/22
14:49
01/22/18
14:49
Technical Analysis
Technical Take: S&P 500 moves to new high, levels to watch »

The S&P 500 (SPX) has…

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

XLI

Industrial Select Sector SPDR

$79.45

-0.24 (-0.30%)

XLB

S&P Select Materials SPDR

$62.93

-0.35 (-0.55%)

XLY

Consumer Discretionary Sector SPDR

$106.28

0.6762 (0.64%)

XLE

Energy Select Sector SPDR

$77.78

1.4 (1.83%)

XLK

Technology Select Sector SPDR

$68.19

0.385 (0.57%)

SPY

SPDR S&P 500 ETF Trust

$281.59

1.181 (0.42%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

CELG

Celgene

$102.65

0.93 (0.91%)

14:40
01/22/18
01/22
14:40
01/22/18
14:40
Options
Celgene calls outpace puts 3:1 as shares tick modestly higher »

Celgene calls outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

14:40
01/22/18
01/22
14:40
01/22/18
14:40
General news
Treasury Action: yields have reversed the earlier declines »

Treasury Action: yields…

GENC

Gencor Industries

14:30
01/22/18
01/22
14:30
01/22/18
14:30
Hot Stocks
Royce & Associates reports 7.37% passive stake in Gencor Industries »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPL

Buckeye Partners

$56.18

1.155 (2.10%)

14:30
01/22/18
01/22
14:30
01/22/18
14:30
Options
Bullish option flow in Buckeye Partners as shares rally »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

CLVS

Clovis

$56.76

0.89 (1.59%)

14:25
01/22/18
01/22
14:25
01/22/18
14:25
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

$NSD

NASDAQ Market Internals

14:17
01/22/18
01/22
14:17
01/22/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/22/18
01/22
14:16
01/22/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYBE

Cyberoptics

$17.15

0.45 (2.69%)

14:05
01/22/18
01/22
14:05
01/22/18
14:05
Hot Stocks
Royce & Associates reports 9.64% passive stake in Cyberoptics »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$34.31

0.81 (2.42%)

14:05
01/22/18
01/22
14:05
01/22/18
14:05
Options
FMC Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CTB

Cooper Tire

$39.65

-0.7 (-1.73%)

14:04
01/22/18
01/22
14:04
01/22/18
14:04
Hot Stocks
Royce & Associates reports 5.14% passive stake in Cooper Tire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTG

Computer Task Group

$5.09

0.12 (2.41%)

14:02
01/22/18
01/22
14:02
01/22/18
14:02
Hot Stocks
Breaking Hot Stocks news story on Computer Task Group »

Royce & Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$85.88

18.185 (26.87%)

14:01
01/22/18
01/22
14:01
01/22/18
14:01
Downgrade
Juno Therapeutics rating change  »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGR

Ingredion

$140.05

2.92 (2.13%)

13:47
01/22/18
01/22
13:47
01/22/18
13:47
Hot Stocks
Ingredion promotes Anthony DeLio to SVP, corporate strategy »

Ingredion Incorporated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ADSK

Autodesk

$115.29

2.74 (2.43%)

13:45
01/22/18
01/22
13:45
01/22/18
13:45
Options
Autodesk call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$47.41

-0.86 (-1.78%)

13:44
01/22/18
01/22
13:44
01/22/18
13:44
Hot Stocks
Breaking Hot Stocks news story on Globant »

JP Morgan Chase reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

NWSA

News Corp.

$17.22

0.21 (1.23%)

, NWS

News Corp

$17.55

0.15 (0.86%)

13:39
01/22/18
01/22
13:39
01/22/18
13:39
Hot Stocks
News Corp. chairman Murdoch makes case for carriage fee for trusted publishers »

News Corp. (NWSA) issued…

NWSA

News Corp.

$17.22

0.21 (1.23%)

NWS

News Corp

$17.55

0.15 (0.86%)

FB

Facebook

$181.29

1.49 (0.83%)

GOOG

Alphabet

$1,137.51

7.72 (0.68%)

GOOGL

Alphabet Class A

$1,143.50

7.53 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

W

Wayfair

$90.98

3.135 (3.57%)

13:35
01/22/18
01/22
13:35
01/22/18
13:35
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

13:35
01/22/18
01/22
13:35
01/22/18
13:35
General news
Treasury Action: yields rebounded towards highs »

Treasury Action: yields…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.